The Experts below are selected from a list of 261 Experts worldwide ranked by ideXlab platform

Lily C. Kao - One of the best experts on this subject based on the ideXlab platform.

  • Randomized trial of long-term Diuretic Therapy for infants with oxygen-dependent bronchopulmonary dysplasia.
    The Journal of Pediatrics, 1994
    Co-Authors: Lily C. Kao, David J. Durand, Ray Mccrea, Martha Birch, Richard J. Powers, Bruce Nickerson
    Abstract:

    Abstract Study objective : To determine whether long-term oral Diuretic Therapy would improve the pulmonary function of preterm infants with bronchopulmonary dysplasia. Design : Randomized, double-blind, placebo-controlled study. Setting : Level III intensive care nursery. Intervention : We randomly selected 43 stable patients with oxygen-dependent bronchopulmonary dysplasia to receive either orally administered spironolactone and chlorothiazide or placebo. These drugs were continued until the patients no longer required supplemental oxygen. Both groups received furosemide as needed. Measurements and results : Each infant had pulmonary function tests at study entry, 4 weeks after study entry, 1 week and 8 weeks after being weaned to room air and off study drugs, and at 1 year of corrected age. Pulmonary function tests included dynamic pulmonary compliance, airway resistance, thoracic gas volume, and maximal expiratory flow at functional residual capacity; most of the infants had functional residual capacity measured. Between the first and second pulmonary function tests (while the infants were receiving Diuretic or placebo), the infants in the Diuretic group had a significant improvement in dynamic pulmonary compliance (46%; p p p Conclusions : Long-term Diuretic Therapy in stable infants with oxygen-dependent bronchopulmonary dyslasia, after extubation, improves their pulmonary function and decreases their fractional inspired oxygen requirement, but does not decrease the number of days that they require supplemental oxygen. The improvement in pulmonary function associated with Diuretic Therapy is not maintained after treatment is discontinued. (J P EDIATR 1994;124:772-81)

  • Randomized trial of long-term Diuretic Therapy for infants with oxygen-dependent bronchopulmonary dysplasia.
    The Journal of pediatrics, 1994
    Co-Authors: Lily C. Kao, David J. Durand, Martha Birch, Richard J. Powers, R C Mccrea, B G Nickerson
    Abstract:

    To determine whether long-term oral Diuretic Therapy would improve the pulmonary function of preterm infants with bronchopulmonary dysplasia. Randomized, double-blind, placebo-controlled study. Level III intensive care nursery. We randomly selected 43 stable patients with oxygen-dependent bronchopulmonary dysplasia to receive either orally administered spironolactone and chlorothiazide or placebo. These drugs were continued until the patients no longer required supplemental oxygen. Both groups received furosemide as needed. Each infant had pulmonary function tests at study entry, 4 weeks after study entry, 1 week and 8 weeks after being weaned to room air and off study drugs, and at 1 year of corrected age. Pulmonary function tests include dynamic pulmonary compliance, airway resistance, thoracic gas volume, and maximal expiratory flow at functional residual capacity; most of the infants had functional residual capacity measured. Between the first and second pulmonary function tests (while the infants were receiving Diuretic or placebo), the infants in the Diuretic group had a significant improvement in dynamic pulmonary compliance (46%; p < 0.001) and airway resistance (31%; p < 0.05); there were no changes in compliance or resistance in the placebo group. Although patients in both the Diuretic and the placebo groups required progressively less supplemental oxygen, by 4 weeks after study entry the patients in the Diuretic group needed less supplemental oxygen than did those in the placebo group (p < 0.01). There were no significant differences in results of serial pulmonary function tests in either group after discontinuation of Diuretic Therapy. Despite the significant differences in pulmonary function between the two groups, there was no significant difference between them in the total number of days that supplemental oxygen was required. Significantly more infantsin the placebo group received more than 10 doses of furosemide on an as-needed basis. Long-term Diuretic Therapy in stable infants with oxygen-dependent bronchopulmonary dysplasia, after extubation, improves their pulmonary function and decreases their fractional inspired oxygen requirement, but does not decrease the number of days that they require supplemental oxygen. The improvement in pulmonary function associated with Diuretic Therapy is not maintained after treatment is discontinued.

Michio Imawari - One of the best experts on this subject based on the ideXlab platform.

  • open labeled randomized controlled trial to compare Diuretic Therapy with recombinant human serum albumin and Diuretic Therapy for therapeutic treatment of ascites in patients with advanced liver cirrhosis an exploratory trial
    Hepatology Research, 2014
    Co-Authors: Toru Nakamura, Michio Sata, Kazuyuki Suzuki, Hisataka Moriwaki, Hiroshi Fukui, Shigetoshi Fujiyama, Michio Imawari
    Abstract:

    Aim There have been only a few trials demonstrating additional effects of human serum albumin (HSA) on Diuretic Therapy in patients with cirrhotic ascites. We aimed to evaluate the safety and efficacy of recombinant HSA, KD-294, treatment in patients with cirrhotic ascites. Methods The inclusion criteria were patients 20–75 years of age, with cirrhotic ascites and a serum albumin concentration of less than 3.0 g/dL. Eighty-five patients were registered and 71 patients underwent randomization. Enrolled patients received oral spironolactone at 50 mg/day and i.v. furosemide at 20 mg/day in addition to low-sodium diet. They were divided randomly into a KD-294 treatment group (n = 35) or non-treatment control group (n = 36). Patients in the KD-294 group received KD-294 at 25 g/day for up to 5 days and those in the control group continued the Diuretic Therapy. They were followed up for 5 weeks. Results KD-294 was well tolerated. A correlation between the increases in serum albumin and decreases in bodyweight was not shown. However, changes of plasma renin concentration (PRC) showed a significant decrease in the KD-294 group compared with the control group. As a result of this exploratory analysis, patients with high PRC showed a significant correlation between increases in serum albumin and decreases in bodyweight. Conclusion The present data do not show efficacy in all patients with cirrhotic ascites, however, they suggest that additional effects of HSA on Diuretic Therapy are expected in high PRC patients.

  • Open‐labeled randomized controlled trial to compare Diuretic Therapy with recombinant human serum albumin and Diuretic Therapy for therapeutic treatment of ascites in patients with advanced liver cirrhosis: An exploratory trial
    Hepatology research : the official journal of the Japan Society of Hepatology, 2013
    Co-Authors: Toru Nakamura, Michio Sata, Kazuyuki Suzuki, Hisataka Moriwaki, Hiroshi Fukui, Shigetoshi Fujiyama, Michio Imawari
    Abstract:

    Aim There have been only a few trials demonstrating additional effects of human serum albumin (HSA) on Diuretic Therapy in patients with cirrhotic ascites. We aimed to evaluate the safety and efficacy of recombinant HSA, KD-294, treatment in patients with cirrhotic ascites. Methods The inclusion criteria were patients 20–75 years of age, with cirrhotic ascites and a serum albumin concentration of less than 3.0 g/dL. Eighty-five patients were registered and 71 patients underwent randomization. Enrolled patients received oral spironolactone at 50 mg/day and i.v. furosemide at 20 mg/day in addition to low-sodium diet. They were divided randomly into a KD-294 treatment group (n = 35) or non-treatment control group (n = 36). Patients in the KD-294 group received KD-294 at 25 g/day for up to 5 days and those in the control group continued the Diuretic Therapy. They were followed up for 5 weeks. Results KD-294 was well tolerated. A correlation between the increases in serum albumin and decreases in bodyweight was not shown. However, changes of plasma renin concentration (PRC) showed a significant decrease in the KD-294 group compared with the control group. As a result of this exploratory analysis, patients with high PRC showed a significant correlation between increases in serum albumin and decreases in bodyweight. Conclusion The present data do not show efficacy in all patients with cirrhotic ascites, however, they suggest that additional effects of HSA on Diuretic Therapy are expected in high PRC patients.

Bruce Nickerson - One of the best experts on this subject based on the ideXlab platform.

  • Randomized trial of long-term Diuretic Therapy for infants with oxygen-dependent bronchopulmonary dysplasia.
    The Journal of Pediatrics, 1994
    Co-Authors: Lily C. Kao, David J. Durand, Ray Mccrea, Martha Birch, Richard J. Powers, Bruce Nickerson
    Abstract:

    Abstract Study objective : To determine whether long-term oral Diuretic Therapy would improve the pulmonary function of preterm infants with bronchopulmonary dysplasia. Design : Randomized, double-blind, placebo-controlled study. Setting : Level III intensive care nursery. Intervention : We randomly selected 43 stable patients with oxygen-dependent bronchopulmonary dysplasia to receive either orally administered spironolactone and chlorothiazide or placebo. These drugs were continued until the patients no longer required supplemental oxygen. Both groups received furosemide as needed. Measurements and results : Each infant had pulmonary function tests at study entry, 4 weeks after study entry, 1 week and 8 weeks after being weaned to room air and off study drugs, and at 1 year of corrected age. Pulmonary function tests included dynamic pulmonary compliance, airway resistance, thoracic gas volume, and maximal expiratory flow at functional residual capacity; most of the infants had functional residual capacity measured. Between the first and second pulmonary function tests (while the infants were receiving Diuretic or placebo), the infants in the Diuretic group had a significant improvement in dynamic pulmonary compliance (46%; p p p Conclusions : Long-term Diuretic Therapy in stable infants with oxygen-dependent bronchopulmonary dyslasia, after extubation, improves their pulmonary function and decreases their fractional inspired oxygen requirement, but does not decrease the number of days that they require supplemental oxygen. The improvement in pulmonary function associated with Diuretic Therapy is not maintained after treatment is discontinued. (J P EDIATR 1994;124:772-81)

B G Nickerson - One of the best experts on this subject based on the ideXlab platform.

  • Randomized trial of long-term Diuretic Therapy for infants with oxygen-dependent bronchopulmonary dysplasia.
    The Journal of pediatrics, 1994
    Co-Authors: Lily C. Kao, David J. Durand, Martha Birch, Richard J. Powers, R C Mccrea, B G Nickerson
    Abstract:

    To determine whether long-term oral Diuretic Therapy would improve the pulmonary function of preterm infants with bronchopulmonary dysplasia. Randomized, double-blind, placebo-controlled study. Level III intensive care nursery. We randomly selected 43 stable patients with oxygen-dependent bronchopulmonary dysplasia to receive either orally administered spironolactone and chlorothiazide or placebo. These drugs were continued until the patients no longer required supplemental oxygen. Both groups received furosemide as needed. Each infant had pulmonary function tests at study entry, 4 weeks after study entry, 1 week and 8 weeks after being weaned to room air and off study drugs, and at 1 year of corrected age. Pulmonary function tests include dynamic pulmonary compliance, airway resistance, thoracic gas volume, and maximal expiratory flow at functional residual capacity; most of the infants had functional residual capacity measured. Between the first and second pulmonary function tests (while the infants were receiving Diuretic or placebo), the infants in the Diuretic group had a significant improvement in dynamic pulmonary compliance (46%; p < 0.001) and airway resistance (31%; p < 0.05); there were no changes in compliance or resistance in the placebo group. Although patients in both the Diuretic and the placebo groups required progressively less supplemental oxygen, by 4 weeks after study entry the patients in the Diuretic group needed less supplemental oxygen than did those in the placebo group (p < 0.01). There were no significant differences in results of serial pulmonary function tests in either group after discontinuation of Diuretic Therapy. Despite the significant differences in pulmonary function between the two groups, there was no significant difference between them in the total number of days that supplemental oxygen was required. Significantly more infantsin the placebo group received more than 10 doses of furosemide on an as-needed basis. Long-term Diuretic Therapy in stable infants with oxygen-dependent bronchopulmonary dysplasia, after extubation, improves their pulmonary function and decreases their fractional inspired oxygen requirement, but does not decrease the number of days that they require supplemental oxygen. The improvement in pulmonary function associated with Diuretic Therapy is not maintained after treatment is discontinued.

David J. Durand - One of the best experts on this subject based on the ideXlab platform.

  • Randomized trial of long-term Diuretic Therapy for infants with oxygen-dependent bronchopulmonary dysplasia.
    The Journal of Pediatrics, 1994
    Co-Authors: Lily C. Kao, David J. Durand, Ray Mccrea, Martha Birch, Richard J. Powers, Bruce Nickerson
    Abstract:

    Abstract Study objective : To determine whether long-term oral Diuretic Therapy would improve the pulmonary function of preterm infants with bronchopulmonary dysplasia. Design : Randomized, double-blind, placebo-controlled study. Setting : Level III intensive care nursery. Intervention : We randomly selected 43 stable patients with oxygen-dependent bronchopulmonary dysplasia to receive either orally administered spironolactone and chlorothiazide or placebo. These drugs were continued until the patients no longer required supplemental oxygen. Both groups received furosemide as needed. Measurements and results : Each infant had pulmonary function tests at study entry, 4 weeks after study entry, 1 week and 8 weeks after being weaned to room air and off study drugs, and at 1 year of corrected age. Pulmonary function tests included dynamic pulmonary compliance, airway resistance, thoracic gas volume, and maximal expiratory flow at functional residual capacity; most of the infants had functional residual capacity measured. Between the first and second pulmonary function tests (while the infants were receiving Diuretic or placebo), the infants in the Diuretic group had a significant improvement in dynamic pulmonary compliance (46%; p p p Conclusions : Long-term Diuretic Therapy in stable infants with oxygen-dependent bronchopulmonary dyslasia, after extubation, improves their pulmonary function and decreases their fractional inspired oxygen requirement, but does not decrease the number of days that they require supplemental oxygen. The improvement in pulmonary function associated with Diuretic Therapy is not maintained after treatment is discontinued. (J P EDIATR 1994;124:772-81)

  • Randomized trial of long-term Diuretic Therapy for infants with oxygen-dependent bronchopulmonary dysplasia.
    The Journal of pediatrics, 1994
    Co-Authors: Lily C. Kao, David J. Durand, Martha Birch, Richard J. Powers, R C Mccrea, B G Nickerson
    Abstract:

    To determine whether long-term oral Diuretic Therapy would improve the pulmonary function of preterm infants with bronchopulmonary dysplasia. Randomized, double-blind, placebo-controlled study. Level III intensive care nursery. We randomly selected 43 stable patients with oxygen-dependent bronchopulmonary dysplasia to receive either orally administered spironolactone and chlorothiazide or placebo. These drugs were continued until the patients no longer required supplemental oxygen. Both groups received furosemide as needed. Each infant had pulmonary function tests at study entry, 4 weeks after study entry, 1 week and 8 weeks after being weaned to room air and off study drugs, and at 1 year of corrected age. Pulmonary function tests include dynamic pulmonary compliance, airway resistance, thoracic gas volume, and maximal expiratory flow at functional residual capacity; most of the infants had functional residual capacity measured. Between the first and second pulmonary function tests (while the infants were receiving Diuretic or placebo), the infants in the Diuretic group had a significant improvement in dynamic pulmonary compliance (46%; p < 0.001) and airway resistance (31%; p < 0.05); there were no changes in compliance or resistance in the placebo group. Although patients in both the Diuretic and the placebo groups required progressively less supplemental oxygen, by 4 weeks after study entry the patients in the Diuretic group needed less supplemental oxygen than did those in the placebo group (p < 0.01). There were no significant differences in results of serial pulmonary function tests in either group after discontinuation of Diuretic Therapy. Despite the significant differences in pulmonary function between the two groups, there was no significant difference between them in the total number of days that supplemental oxygen was required. Significantly more infantsin the placebo group received more than 10 doses of furosemide on an as-needed basis. Long-term Diuretic Therapy in stable infants with oxygen-dependent bronchopulmonary dysplasia, after extubation, improves their pulmonary function and decreases their fractional inspired oxygen requirement, but does not decrease the number of days that they require supplemental oxygen. The improvement in pulmonary function associated with Diuretic Therapy is not maintained after treatment is discontinued.